Guangdong Marubi Biotechnology Co., Ltd.
Shanghai Stock ExchangeTotal Valuation
Guangdong Marubi Biotechnology Co., Ltd. carries a market capitalization of 12.48B, placing it among publicly traded companies globally. Its enterprise value stands at 9.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 12.48B |
| Enterprise Value | 9.58B |
Share Statistics
Guangdong Marubi Biotechnology Co., Ltd. currently has 401.00M shares outstanding.
| Shares Outstanding | 401.00M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
Guangdong Marubi Biotechnology Co., Ltd. trades at a trailing price-to-earnings ratio of 69.06. The price-to-sales ratio is 3.81, and the price-to-book ratio stands at 4.34.
| PE Ratio | 69.06 |
| PS Ratio | 3.81 |
| PB Ratio | 4.34 |
| P/TBV Ratio | 3.45 |
| P/FCF Ratio | 68.31 |
| P/OCF Ratio | N/A |
Enterprise Valuation
On an enterprise value basis, Guangdong Marubi Biotechnology Co., Ltd. trades at an EV/EBITDA multiple of 48.35 and an EV/FCF ratio of 59.60. The EV/Sales ratio of 3.41 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 48.35 provides insight into valuation relative to core operating earnings.
| EV / Sales | 3.41 |
| EV / EBITDA | 48.35 |
| EV / EBIT | 48.35 |
| EV / FCF | 59.60 |
Financial Position
Guangdong Marubi Biotechnology Co., Ltd. maintains a current ratio of 1.97, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 13.45, indicating elevated leverage, while an interest coverage ratio of 39.10 demonstrates strong ability to service its debt obligations.
| Current Ratio | 1.97 |
| Quick Ratio | 1.41 |
| Debt / Equity | 13.45 |
| Debt / EBITDA | 2.37 |
| Interest Coverage | 39.10 |
Financial Efficiency
Guangdong Marubi Biotechnology Co., Ltd. posts a return on equity of 6.17 and a return on invested capital of 3.78.
| Return on Equity (ROE) | 6.17 |
| Return on Assets (ROA) | 3.27 |
| Return on Invested Capital (ROIC) | 3.78 |
| Return on Capital Employed (ROCE) | 5.29 |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 3.22 |
Taxes
Over the trailing twelve months, Guangdong Marubi Biotechnology Co., Ltd. has paid 43.13M in income taxes, reflecting an effective tax rate of 22.11.
| Income Tax | 43.13M |
| Effective Tax Rate | 22.11 |
Stock Price Statistics
Guangdong Marubi Biotechnology Co., Ltd.'s stock has declined approximately -26.15093% over the past 52 weeks. The 50-day moving average sits at 24.20, while the 200-day moving average is 30.25.
| Beta (5Y) | N/A |
| 52-Week Price Change | -26.15093% |
| 50-Day Moving Average | 24.20 |
| 200-Day Moving Average | 30.25 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, Guangdong Marubi Biotechnology Co., Ltd. generated 2.81B in revenue and converted that into 155.06M in net income, yielding earnings per share of 0.38. EBITDA reached 198.12M, while operating income came in at 198.12M.
| Revenue | 2.81B |
| Gross Profit | 2.06B |
| Operating Income | 198.12M |
| Pretax Income | 195.06M |
| Net Income | 155.06M |
| EBITDA | 198.12M |
| EBIT | 198.12M |
| Earnings Per Share (EPS) | 0.38 |
Balance Sheet
Guangdong Marubi Biotechnology Co., Ltd. holds 1.66B in cash and equivalents against 469.62M in total debt, resulting in a net debt position of -836.29M. Total book value stands at 2.47B, with working capital of 1.14B providing operational flexibility.
| Cash & Cash Equivalents | 1.66B |
| Total Debt | 469.62M |
| Net Debt | -836.29M |
| Equity (Book Value) | 2.47B |
| Book Value Per Share | 6.11 |
| Working Capital | 1.14B |
Cash Flow
After subtracting -156.77M in capital expenditures, free cash flow totaled -156.77M - equivalent to -0.39 per share.
| Operating Cash Flow | N/A |
| Capital Expenditures | -156.77M |
| Free Cash Flow | -156.77M |
| FCF Per Share | -0.39 |
Margins
Guangdong Marubi Biotechnology Co., Ltd. operates with a gross margin of 73.26, reflecting its pricing power and cost economics. The operating margin of 7.04 and net profit margin of 5.51 provide insight into operational efficiency.
| Gross Margin | 73.26 |
| Operating Margin | 7.04 |
| Pretax Margin | 6.93 |
| Profit Margin | 5.51 |
| EBITDA Margin | 7.04 |
Dividends & Yields
The company's payout ratio of 202.10 indicates the proportion of earnings distributed to shareholders.
| Dividend Per Share | 0.74 |
| Dividend Yield | N/A |
| Payout Ratio | 202.10 |
| Shareholder Yield | 4.06 |
| FCF Yield | 1.46 |
Scores
Guangdong Marubi Biotechnology Co., Ltd. posts an Altman Z-Score of 7.16, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 7.16 |